Drugs / BNT3212
last change Aug 2025 re-read 2 minutes ago

BNT3212

Developed for
neoplastic disease or syndrome
Investigated by
BioNTech (Shanghai) Pharmaceuticals Co., Ltd. · BioNTech SE · Biotheus (Hengqin) Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07147348 Aug 2025 → Nov 2027 expected neoplastic disease or syndrome BioNTech SE Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BNT3212 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07147348